Furthermore, findings from the KEYNOTE-042 and KEYNOTE-024 trials demonstrated that PD-1 inhibitors (e.g., pembrolizumab) show differential efficacy in advanced NSCLC patients depending on PD-L1 expression levels. The gene discussed is CD274; the disease is non-small cell lung carcinoma.